Baxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government to supply required quantities of swine flu vaccine, Celvapan. The company has supplied only half of the 400,000 doses of Celvapan it had agreed to supply by the end of Aug 2009.

Britain’s Department of Health allocated Baxter 30 million of the 90 million doses of a $745 million (?450 million) contract placed in May 2009. The remaining 60 million doses were allocated to GlaxoSmithKline plc (GSK).

Baxter has already received contracts from five governments Incorporatedluding the Governments of Ireland and New Zealand, for 80 million doses of swine flu vaccines. The company has decided not to sign any more contracts since it is already running behind schedule.

The U.K. government is working with Baxter to speed up things and improve the supply of vaccines. The government is not seeking any compensation from Baxter right now.

We think that the delay in the delivery of vaccines will damage the reputation of Baxter as a leading contributor to the welfare of society. Most importantly, it will deprive people who are suffering from this pandemic from the right medicine.

Baxter is a leading global medical products and services company that develops, manufactures and markets products to save the lives of millions of people affected by hemophilia, kidney disease, infectious diseases, etc.

Baxter’s main competitors include Becton, Dickinson and Company (BDX) and Johnson & Johnson (JNJ). Baxter’s products are primarily life-sustaining, a hedge against the current economic turmoil

Zacks Investment Research
View original at: Zacks.com News Feed

1. (SNY) FDA Approves First H1N1 VaccineIn a major achievement towards vaccinating people against the H1N1 virus, yesterday the US Food...
2. (AZN) Almost 25 Pharmaceutical Companies are Racing to Bring H1N1the Vaccine to MarketAlthough we are waiting eagerly for the first H1N1 vaccine to hit the market, it...
3. ($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the...
4. (BAX) Baxter International Inc. – Growth And Income – Zacks Rank BuyBaxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early...
5. (BAX) Baxter International, Inc. – Growth And Income – Zacks Rank BuyBaxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting...
6. (BAX) Baxter International – ROE of 31% more than doubles the industry average of 12%Baxter International Inc. (BAX) recently reported record results for 2008, surpassing its guidance. The company...

Search Posts by Tag: BAX | Baxter International | BDX | Becton | Dickinson And Company | Glaxosmithkline plc | GSK | JNJ | Johnson & Johnson | Healthcare | Medical Instruments & Supplies

RSS Feeds by Tag: BAX | Baxter International | BDX | Becton | Dickinson And Company | Glaxosmithkline plc | GSK | JNJ | Johnson & Johnson | Healthcare | Medical Instruments & Supplies |

Other Posts by: vitalstocks | RSS Feed for this author